SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS LTD. ATELLICA IM HBC TOTAL 2 (HBCT2); TEST, HEPATITIS B (B CORE, BE ANTIGEN, BE ANTIBODY, B CORE IGM)
|
Back to Search Results |
|
Model Number N/A |
Device Problem
False Negative Result (1225)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 10/29/2023 |
Event Type
malfunction
|
Event Description
|
The customer reports observation of nonreactive (negative) atellica im hbc total 2 (hbct2) results which were discordant relative to alternate-method testing.Hbct2 lot 008 was in use at the time.A nonreactive (negative) hbct2 result was obtained for a 28-year-old male patient with a history of a positive ahbct result 6 months earlier.This negative result was not reported to the physician.Re-testing of the same sample using the atellica im anti-hepatitis b core total (hbct) test produced a reactive (positive) result.The customer sent this patient¿s sample to another laboratory for confirmation.There are no allegations of patient harm, changes in treatment, or delays of diagnosis in association with the observed discordance.
|
|
Manufacturer Narrative
|
A customer from outside the united states reported observation of a nonreactive (negative) atellica im hbc total 2 (hbct2) results which were discordant relative to patient history and alternate-method testing.Testing was repeated for investigation purposes.Both methods (hbct2 and hbct) reproduced the initial observations: negative by hbct2, positive by hbct.The assay's instructions for use (ifu) states the following, under limitations: "the performance of the assay has not been established for populations of immunocompromised or immunosuppressed patients." "patient samples may contain heterophilic antibodies that could react in immunoassays to give falsely elevated or depressed results.This assay is designed to minimize interference from heterophilic antibodies.Additional information may be required for diagnosis." siemens is investigating.
|
|
Manufacturer Narrative
|
Mdr 1219913-2023-00283 was initially submitted on 2023-11-07.A customer from outside the united states reported observation of nonreactive (negative) atellica im hbc total 2 (hbct2) results which were discordant relative to alternate-method testing.Atellica im hbct2 results for this patient were reproducibly negative, while hbct results were reactive (positive).The patient's sample was tested at an external lab using a third method, and a negative result was returned.Based on the available information, the probable cause for the discordant results is a sample-specific assay interferent.The customer is operational, and no product problem was identified.Note: in section h6, the codes for investigation findings and investigation conclusion have been updated.Manufacturer information in section d3 has been corrected.
|
|
Search Alerts/Recalls
|
|
|